Investors Who Lost Money on Cerevel Therapeutics Holdings, Inc. Invited to Join Class Action Lawsuit
On April 18, 2025, Levi & Korsinsky, LLP issued a notice to investors regarding a class action lawsuit concerning Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). This class action lawsuit aims to recover losses sustained by those who were impacted by alleged securities fraud involving the company.
The class defined in the lawsuit includes all individuals or entities that:
(a) sold or otherwise disposed of Cerevel's publicly-traded common stock from October 11, 2023, to August 1, 2024;
(b) held shares of Cerevel as of the record date on January 8, 2024, and were eligible to vote on the merger with AbbVie Inc.;
(c) sold Cerevel stock around October 16, 2023, coinciding with Bain Capital's acquisition of shares from the offering.
If you're one of the investors impacted, further details can be found here. You can also reach out to Joseph E. Levi, Esq. via email at info@zlk.com or call (212) 363-7500 for assistance.
The essence of the complaint highlights critical information omitted in Cerevel's documentation related to its October 16, 2023, secondary offering. The presented materials allegedly lacked important facts regarding AbbVie's interest in acquiring Cerevel, which was at a price substantially higher than the $22.81 offered per share. This misinformation resulted in a manipulated decline in Cerevel's stock price until the merger announcement was made.
Bain Capital Investors, LLC, the controlling shareholder of Cerevel, reportedly obtained shares from the secondary offering at this artificially depressed price, while having access to nonpublic material information about AbbVie's acquisition intentions. On December 6, 2023, the company made it known that AbbVie would acquire Cerevel at a valuation of $45 per share. This led Bain to profit over $120 million from its investments during a period of reported price manipulation. Furthermore, Cerevel's Proxy statement released on January 18, 2024, allegedly misled investors regarding the timing and nature of AbbVie’s interest in the company.
For investors who endured financial losses in Cerevel Therapeutics Holdings, Inc., it is crucial to note that you have until June 3, 2025, to express your wish to be appointed as lead plaintiff in this case. However, participating in the recovery process does not necessitate serving in that particular role.
An important aspect of this class action is the lack of any upfront cost to participants. If you are deemed a class member, you might be eligible for compensation without incurring any fees or expenses upfront. Your participation does not incur any obligation or cost, making it a viable option to seek redress for your losses.
Levi & Korsinsky has established a reputation over the past twenty years for winning complex securities cases and securing substantial financial recovery for compromised shareholders. Ranked among the top securities litigation firms in the U.S. by ISS Securities Class Action Services for seven consecutive years, they are equipped to assist investors in navigating this legal landscape.
If you're an affected investor, timely action is crucial. Do not hesitate to contact Levi & Korsinsky for a free consultation on your rights and the potential for joining this class action. Their commitment to obtaining justice for aggrieved shareholders remains unwavering, ensuring a robust legal support system for those in need.
The class defined in the lawsuit includes all individuals or entities that:
(a) sold or otherwise disposed of Cerevel's publicly-traded common stock from October 11, 2023, to August 1, 2024;
(b) held shares of Cerevel as of the record date on January 8, 2024, and were eligible to vote on the merger with AbbVie Inc.;
(c) sold Cerevel stock around October 16, 2023, coinciding with Bain Capital's acquisition of shares from the offering.
If you're one of the investors impacted, further details can be found here. You can also reach out to Joseph E. Levi, Esq. via email at info@zlk.com or call (212) 363-7500 for assistance.
The essence of the complaint highlights critical information omitted in Cerevel's documentation related to its October 16, 2023, secondary offering. The presented materials allegedly lacked important facts regarding AbbVie's interest in acquiring Cerevel, which was at a price substantially higher than the $22.81 offered per share. This misinformation resulted in a manipulated decline in Cerevel's stock price until the merger announcement was made.
Bain Capital Investors, LLC, the controlling shareholder of Cerevel, reportedly obtained shares from the secondary offering at this artificially depressed price, while having access to nonpublic material information about AbbVie's acquisition intentions. On December 6, 2023, the company made it known that AbbVie would acquire Cerevel at a valuation of $45 per share. This led Bain to profit over $120 million from its investments during a period of reported price manipulation. Furthermore, Cerevel's Proxy statement released on January 18, 2024, allegedly misled investors regarding the timing and nature of AbbVie’s interest in the company.
For investors who endured financial losses in Cerevel Therapeutics Holdings, Inc., it is crucial to note that you have until June 3, 2025, to express your wish to be appointed as lead plaintiff in this case. However, participating in the recovery process does not necessitate serving in that particular role.
An important aspect of this class action is the lack of any upfront cost to participants. If you are deemed a class member, you might be eligible for compensation without incurring any fees or expenses upfront. Your participation does not incur any obligation or cost, making it a viable option to seek redress for your losses.
Levi & Korsinsky has established a reputation over the past twenty years for winning complex securities cases and securing substantial financial recovery for compromised shareholders. Ranked among the top securities litigation firms in the U.S. by ISS Securities Class Action Services for seven consecutive years, they are equipped to assist investors in navigating this legal landscape.
If you're an affected investor, timely action is crucial. Do not hesitate to contact Levi & Korsinsky for a free consultation on your rights and the potential for joining this class action. Their commitment to obtaining justice for aggrieved shareholders remains unwavering, ensuring a robust legal support system for those in need.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.